The serious infection risk of infliximab was examined among people with severe psoriasis in a cohort study using real-world data from BADBIR. Propensity score method and inverse probability of treatment weights were used to balance covariates across treatment groups. Andersen-Gill recurrent Cox model was used to estimate hazard ratios for comparisons with infliximab. Our findings suggest that infliximab is associated with an increased risk of serious infection compared to adalimumab, secukinumab, ustekinumab and standard treatments.
Bright et al. (Tue,) studied this question.